What can Mark Bomback's previous gigs tell us about the steamy adaptation? MTV News takes some clues from 'Unstoppable' and more.
By Alex Zalben
Bellator MMA’s return to the Revel Casino in Atlantic City, New Jersey is set for Bellator 108 on November 15 but with one major addition. Joining the broadcast will be a light heavyweight pairing between Quinton “Rampage” Jackson and Joey Beltran. Bellator MMA officials announced the new main event earlier today via press release.
“Rampage” was originally set to face Tito Ortiz this weekend at Bellator 106 before Ortiz was forced out with a neck injury. While Bellator MMA officials tried to find an opponent for this weekend, Jackson’s debut will be delayed for two weeks to make the pairing with Beltran.
Beltran comes into the bout fresh off a second release from the UFC following his narrow split decision loss to Fábio Maldonado at UFC Fight Night 29. While Beltran did get a victory in his second UFC stint, the result was overturned following a positive test for steroids.
The November 15 pairing will serve as both fighters’ Bellator MMA debut.
While the card already had a headliner between Bellator middleweight champion Alexander Shlemenko and Season 8 tournament winner Doug Marshall, the card will also feature the Season 9 tournament final pitting Patricio Freire against Justin Wilcox. Bellator 108 will air live via Spike TV with the prelims airing via Spike.com.
Bellator 108 Fight Card:
Main Card (8PM ET Spike TV)
Preliminary Card (6PM ET Spike.com)
For the latest Bellator 108 updates and Bellator MMA News, stay tuned to MMAFrenzy.
Would you wear these outfits? You be the judge about the stars' (Lea! Gaga!) fashion choices.
Source: http://www.ivillage.com/celebrity-style-were-iffy-about-likes-or-yikes/1-b-67322?dst=iv%3AiVillage%3Acelebrity-style-were-iffy-about-likes-or-yikes-67322A contentious and costly battle is taking shape in Colorado around the practice of hydraulic fracturing. In November, four communities will vote on local ballot issues seeking to limit or ban fracking. A similar measure is on the ballot in Ohio. Proponents say they're worried about health and environmental effects of the practice.
![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_ut133zWJ9aFJx50h-2rkxISBMMXKMVsM6EAUlc-chIdSthpG51QG6xXOU4K305AI6kF3d-XN3KgIUMpKQAB3jsOBd7lQbpd63oaXc2l5Q=s0-d){kind=small}
PUBLIC RELEASE DATE: 30-Oct-2013
ShareContact: Matthias Tschoep
matthias.tschoep@helmholtz-muenchen.de
49-893-187-2103
Helmholtz Zentrum Mnchen - German Research Center for Environmental Health
Scientists from the Helmholtz Zentrum Muenchen and the Technische Universitaet Muenchen, together with scientists in the USA, have developed a new therapeutic approach for treatment of Type 2 diabetes. A novel single molecule hormone, which acts equally on the receptors of the insulin-stimulating hormones GLP-1 and GIP, was observed to reduce weight and improve blood sugar.
The results have now been published in the medical journal Science Translational Medicine, and include data from successful clinical studies in partnership with the pharmaceutical company Roche.
GLP-1 (glucagon-like peptide 1) and GIP (gastric inhibitory peptide) are hormones that are formed by the digestive tract and that control food intake and numerous metabolic processes. When glucose (sugar) is ingested, these hormones primarily lead to increased insulin release and subsequent reduction in blood sugar, but they also affect appetite regulation and fat burning.
Some of the actions, which are combined in one molecule for the first time, are already in use for the treatment of type 2 diabetes. GLP-1 analogues, as well as DPP4 (dipeptidyl peptidase 4) inhibitors, which are thought to enhance GLP-1 action, are used to reduce blood sugar. A HMGU and TUM team led by Dr. Brian Finan and Prof. Dr. Matthias Tschp at the Helmholtz Diabetes Center, working with Richard DiMarchi from Indiana University and colleagues from the University of Cincinnati, have now succeeded in developing a molecular structure that combines the effects of the two hormones. These novel molecules simultaneously stimulate two receptors (GLP-1 and GIP) and consequently maximize metabolic effects compared to each of the individual molecules, or currently available medicines that are based on individual intestinal hormones.
The newly discovered GLP-1/GIP co-agonists lead to improved blood sugar levels and to a significant weight loss and lower blood fat. Importantly, the researchers observed that the new substance also improved metabolism in humans, in addition to beneficial effects they discovered in several animal models. At the same time, there are indications that possible adverse effects, the most frequent of which are gastrointestinal complaints, are less common and less pronounced with this approach than with the individual hormones.
"Our results give us additional confidence that our combinatorial approach of modulating brain regulatory centers via natural gut hormone signals has superior potential for a transformative diabetes treatment", explains Prof. Tschp. He adds a note of caution however: "Still, this approach has to go through several more years of intense research, clinical testing, and safety evaluations, before these substances may become available for patients". Dr. Finan, the first author of the study, points out that there may be unprecedented potential: "We are quite excited about this new multi-functional agent approach and believe it could become an integral part of a next generation of personalized therapies for type 2 diabetes, as the ratio of the GLP-1 and GIP signal strengths could be adjusted depending on the individual needs of patients." The studies which were just published in Science Translational Medicine are perfectly aligned with the research objective of at the Helmholtz Zentrum Mnchen, partner of the German Center for Diabetes Research (DZD), which is to establish new approaches to the diagnosis, therapy and prevention of civilization's major widespread diseases and to further develop these approaches as quickly as possible in the context of translational research in order to provide specific benefits for society.
###
Further information
Original publication:
Finan, B. et al. (2013). Novel Unimolecular Dual-Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans, Science Translational Medicine, doi: 10.1126/scitranslmed.3007218
As German Research Center for Environmental Health, Helmholtz Zentrum Mnchen pursues the goal of developing personalized medical approaches for the prevention and therapy of major common diseases such as diabetes mellitus and lung diseases. To achieve this, it investigates the interaction of genetics, environmental factors and lifestyle. The Helmholtz Zentrum Mnchen has about 2,100 staff members and is headquartered in Neuherberg in the north of Munich. Helmholtz Zentrum Mnchen is a member of the Helmholtz Association, a community of 18 scientific-technical and medical-biological research centers with a total of about 34,000 staff members.
The German Center for Diabetes Research (DZD) brings together experts in the field of diabetes research and interlinks basic research, epidemiology and clinical applications. Members are the German Diabetes Center in Dsseldorf, the German Institute of Human Nutrition (DIfE) in Potsdam-Rehbrcke, Helmholtz Zentrum Mnchen German Research Center for Environmental Health, the Paul Langerhans Institutes of the University Hospital Carl Gustav Carus in Dresden and the University of Tbingen, as well as the Gottfried Wilhelm Leibniz Association and the Helmholtz Association of German Research Centres. The objective of the DZD is to find answers to open questions in diabetes research by means of a novel, integrative research approach and to make a significant contribution to improving the prevention, diagnosis and treatment of diabetes mellitus.
The Institute of Diabetes and Obesity (IDO) studies the diseases of the metabolic syndrome by means of systems biological and translational approaches on the basis of cellular systems, genetically modified mouse models and clinical intervention studies. It seeks to discover new signaling pathways in order to develop innovative therapeutic approaches for the personalized prevention and treatment of obesity, diabetes and their concomitant diseases. IDO is part of the Helmholtz Diabetes Center (HDC).
Share
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
PUBLIC RELEASE DATE: 30-Oct-2013
ShareContact: Matthias Tschoep
matthias.tschoep@helmholtz-muenchen.de
49-893-187-2103
Helmholtz Zentrum Mnchen - German Research Center for Environmental Health
Scientists from the Helmholtz Zentrum Muenchen and the Technische Universitaet Muenchen, together with scientists in the USA, have developed a new therapeutic approach for treatment of Type 2 diabetes. A novel single molecule hormone, which acts equally on the receptors of the insulin-stimulating hormones GLP-1 and GIP, was observed to reduce weight and improve blood sugar.
The results have now been published in the medical journal Science Translational Medicine, and include data from successful clinical studies in partnership with the pharmaceutical company Roche.
GLP-1 (glucagon-like peptide 1) and GIP (gastric inhibitory peptide) are hormones that are formed by the digestive tract and that control food intake and numerous metabolic processes. When glucose (sugar) is ingested, these hormones primarily lead to increased insulin release and subsequent reduction in blood sugar, but they also affect appetite regulation and fat burning.
Some of the actions, which are combined in one molecule for the first time, are already in use for the treatment of type 2 diabetes. GLP-1 analogues, as well as DPP4 (dipeptidyl peptidase 4) inhibitors, which are thought to enhance GLP-1 action, are used to reduce blood sugar. A HMGU and TUM team led by Dr. Brian Finan and Prof. Dr. Matthias Tschp at the Helmholtz Diabetes Center, working with Richard DiMarchi from Indiana University and colleagues from the University of Cincinnati, have now succeeded in developing a molecular structure that combines the effects of the two hormones. These novel molecules simultaneously stimulate two receptors (GLP-1 and GIP) and consequently maximize metabolic effects compared to each of the individual molecules, or currently available medicines that are based on individual intestinal hormones.
The newly discovered GLP-1/GIP co-agonists lead to improved blood sugar levels and to a significant weight loss and lower blood fat. Importantly, the researchers observed that the new substance also improved metabolism in humans, in addition to beneficial effects they discovered in several animal models. At the same time, there are indications that possible adverse effects, the most frequent of which are gastrointestinal complaints, are less common and less pronounced with this approach than with the individual hormones.
"Our results give us additional confidence that our combinatorial approach of modulating brain regulatory centers via natural gut hormone signals has superior potential for a transformative diabetes treatment", explains Prof. Tschp. He adds a note of caution however: "Still, this approach has to go through several more years of intense research, clinical testing, and safety evaluations, before these substances may become available for patients". Dr. Finan, the first author of the study, points out that there may be unprecedented potential: "We are quite excited about this new multi-functional agent approach and believe it could become an integral part of a next generation of personalized therapies for type 2 diabetes, as the ratio of the GLP-1 and GIP signal strengths could be adjusted depending on the individual needs of patients." The studies which were just published in Science Translational Medicine are perfectly aligned with the research objective of at the Helmholtz Zentrum Mnchen, partner of the German Center for Diabetes Research (DZD), which is to establish new approaches to the diagnosis, therapy and prevention of civilization's major widespread diseases and to further develop these approaches as quickly as possible in the context of translational research in order to provide specific benefits for society.
###
Further information
Original publication:
Finan, B. et al. (2013). Novel Unimolecular Dual-Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans, Science Translational Medicine, doi: 10.1126/scitranslmed.3007218
As German Research Center for Environmental Health, Helmholtz Zentrum Mnchen pursues the goal of developing personalized medical approaches for the prevention and therapy of major common diseases such as diabetes mellitus and lung diseases. To achieve this, it investigates the interaction of genetics, environmental factors and lifestyle. The Helmholtz Zentrum Mnchen has about 2,100 staff members and is headquartered in Neuherberg in the north of Munich. Helmholtz Zentrum Mnchen is a member of the Helmholtz Association, a community of 18 scientific-technical and medical-biological research centers with a total of about 34,000 staff members.
The German Center for Diabetes Research (DZD) brings together experts in the field of diabetes research and interlinks basic research, epidemiology and clinical applications. Members are the German Diabetes Center in Dsseldorf, the German Institute of Human Nutrition (DIfE) in Potsdam-Rehbrcke, Helmholtz Zentrum Mnchen German Research Center for Environmental Health, the Paul Langerhans Institutes of the University Hospital Carl Gustav Carus in Dresden and the University of Tbingen, as well as the Gottfried Wilhelm Leibniz Association and the Helmholtz Association of German Research Centres. The objective of the DZD is to find answers to open questions in diabetes research by means of a novel, integrative research approach and to make a significant contribution to improving the prevention, diagnosis and treatment of diabetes mellitus.
The Institute of Diabetes and Obesity (IDO) studies the diseases of the metabolic syndrome by means of systems biological and translational approaches on the basis of cellular systems, genetically modified mouse models and clinical intervention studies. It seeks to discover new signaling pathways in order to develop innovative therapeutic approaches for the personalized prevention and treatment of obesity, diabetes and their concomitant diseases. IDO is part of the Helmholtz Diabetes Center (HDC).
Share
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Taking note of how customers have been working with its Hadoop distribution, Cloudera has expanded the scope of its software so that it can serve as a hub for all of an organization's data, not just data undergoing Hadoop MapReduce analysis.
Some of Cloudera's enterprise customers have "started to use our platform in a new way, as the center of their data centers," said Mike Olson, Cloudera's chairman and chief strategy officer.
[ Also on InfoWorld: Hadoop is not enough for big data, says Facebook analytics chief. | Harness the power of Hadoop with InfoWorld's 7 top tools for taming big data. | Discover what's new in business applications with InfoWorld's Technology: Applications newsletter. ]
"We think this is a very big deal. It will change the way the industry thinks about data," Olson said.
Cloudera has released a new beta of its commercial distribution, Cloudera Enterprise, that provides tools for managing an organization's data, as well as tools from Cloudera and third parties for data analysis.
Olson announced the beta of Cloudera Enterprise 5 at the O'Reilly Strata-Hadoop World conference, being held this week in New York.
"It used to be that an organization had lots of balkanized data silos," Olson said. "The stuff that you used to run on a data warehouse because you had no choice, now you can run on the hub."
Putting the data in a Hadoop-based storage repository has many advantages, Olson argued. You can run different types of analytical workloads against the data in the hub. It can easily feed data to other systems, such as content management systems. It can work as an archiving system.
An enterprise data hub, Olson said, can store data as it is generated, even if the organization isn't sure how the data will be needed. Such data may be valuable later for machine learning analysis or other uses not considered.
An enterprise hub also puts security and governance mechanisms in place to safeguard the data. Cloudera has been working on these tools for several releases, Olson said.
"Our ambition is to draw more workloads in and make the hub more valuable over time," he said.
Part of Hadoop's newfound ability to act as a data hub comes from software additions in the latest version of the open-source software, Apache Hadoop 2, on which Cloudera Enterprise is built.
The inclusion of YARN (Yet Another Resource Manager), for instance, allows Hadoop to handle multiple analysis applications, not just those that run on the batch process-oriented MapReduce.
To facilitate the hub, Cloudera has also set up a management framework that third-party analysis applications can plug into. SAS, Revolution Analytics, Syncsort and other organizations have ported some of their software to the platform. Porting analysis software requires that the operations be executed in parallel, as data in Hadoop is typically distributed across multiple nodes, Olson said.
Cloudera Enterprise 5 also adds the ability to cache HDFS (Hadoop Distributed File System) contents in the working memory of a server, which can boost query response and data processing times.
The company's Navigator auditor tool now allows analysts and data modelers to search, explore, define and tag datasets. Users can add customized queries to Cloudera's Impala SQL engine. And Cloudera Enterprise 5 can work with the NFS (Network File System) nodes, which should make the process of injecting data into HDFS much easier, Olson said.
The software also now can take snapshots of the data, providing a backup if the original data is lost or destroyed.
Joab Jackson covers enterprise software and general technology breaking news for The IDG News Service. Follow Joab on Twitter at @Joab_Jackson. Joab's e-mail address is Joab_Jackson@idg.com.
FILE - This Aug. 1, 2013 file photo shows R&B singer-songwriter Robin Thicke in New York. Two of Marvin Gaye's children, Nona and Frankie Gaye, countersued Thicke and his collaborators on the hit song "Blurred Lines" on Wednesday, Oct. 30, 2013, in Los Angeles claiming the singers improperly copied their father's hit "Got to Give It Up." (Photo by Victoria Will/Invision/AP, File)
FILE - This Aug. 1, 2013 file photo shows R&B singer-songwriter Robin Thicke in New York. Two of Marvin Gaye's children, Nona and Frankie Gaye, countersued Thicke and his collaborators on the hit song "Blurred Lines" on Wednesday, Oct. 30, 2013, in Los Angeles claiming the singers improperly copied their father's hit "Got to Give It Up." (Photo by Victoria Will/Invision/AP, File)
LOS ANGELES (AP) — Two of Marvin Gaye's children sued Robin Thicke and his collaborators on the hit song "Blurred Lines" on Wednesday, accusing them of copyright infringement and alleging music company EMI failed to protect their father's legacy.
Nona Marvisa Gaye and Frankie Christian Gaye's suit is the latest salvo in a dispute over Thicke's hit and whether it copies elements of Gaye's song "Got to Give It Up."
Their lawsuit seeks to block Thicke and collaborators Pharrell and T.I. from using elements of their father's music in "Blurred Lines" or other songs.
Thicke has denied copying Gaye's song for "Blurred Lines," which has the longest streak this year atop the Billboard Hot 100 chart and has sold more than 6 million tracks so far. The suit also accused Thicke of improperly using Gaye's song "After the Dance" in his song "Love After War."
Much of the lawsuit focuses on claims that EMI should have pursued a copyright infringement claim. It also alleges the company's executives used intimidation to try to stop the Gaye family from pursuing a lawsuit.
The suit claims EMI, which is owned by Sony/ATV Music Publishing, has allowed a conflict of interest between the family's rights and the profits it is earning from "Blurred Lines" sales.
"This conflict has resulted in EMI's intentional decision to align themselves with the ('Blurred Lines') writers, without regard to the harm inflicted upon the rights and interests of the Gaye Family, and the legacy of Marvin Gaye," the lawsuit states.
Sony-ATV said it takes "very seriously" its role of protecting its songwriters' works from infringement.
"While we have not yet seen the claims by the Gaye family against EMI, we have repeatedly advised the Gaye family's attorney that the two songs in question have been evaluated by a leading musicologist who concluded that 'Blurred Lines' does not infringe 'Got To Give It Up,'" the company said in a statement.
Sony-ATV also said that while it treasures Marvin Gaye's works and the company's relationship with his family, "we regret that they have been ill-advised in this matter."
Thicke and his collaborators filed a case in August asking a federal judge to rule that the singers did not copy "Got to Give It Up" for their hit.
Howard King, who represents the singers, said the Gayes' countersuit was not unexpected, but he said their decision to sue EMI demonstrates the family lacks the appropriate authority to pursue the case against his clients.
He rejected the notion that EMI turned a blind eye to improper copying of Gaye's music. "EMI is in the business of collecting money for infringements," King said.
The company likely consulted a musicologist who found nothing improper, the attorney said. King said his firm consulted three music experts who determined the notes in the two songs were different.
Gaye's son Marvin Gaye III also might pursue legal action over the song, but he is not included in the federal court suit filed Wednesday.
___
Anthony McCartney can be reached at http://twitter.com/mccartneyAP
Associated PressSource: http://hosted2.ap.org/APDEFAULT/4e67281c3f754d0696fbfdee0f3f1469/Article_2013-10-30-Blurred%20Lines-Song%20Dispute/id-6757b55d901542259c90f7faecb5b52b